Results 181 to 190 of about 2,657,857 (302)

Implementation and use of risk minimization control tools in the EU: A multistakeholder survey

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. Methods We conducted
Sharon C. M. Essink   +21 more
wiley   +1 more source

Benzodiazepines use in primary care England: Prescribing patterns and adverse consequences

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Benzodiazepines (BZDs) are commonly prescribed for anxiety and insomnia but carry risks such as dependence, adverse drug reactions (ADRs) and mortality. Despite deprescribing efforts, the influence of recent prescribing trends, COVID‐19 and adverse outcomes on prescribing patterns in England remains uncertain.
Alvina Chaudhry   +3 more
wiley   +1 more source

Systematic review of clinical trials and cohort studies evaluating HIV post‐exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background We conducted a systematic review of clinical trials and cohort studies on HIV post‐exposure prophylaxis (PEP) regimens to inform updated 2025 Canadian guidelines. Methods We searched Medline and Embase (July 2017–June 2024) for studies reporting on: HIV acquisition, PEP completion, adverse events (AEs) leading to discontinuation and/
Stanley O. Onyegbule   +12 more
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonists in schizophrenia spectrum disorders: A systematic review and meta‐analysis of efficacy, safety and mental health outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The purpose of this study is to evaluate efficacy, safety and mental‐health outcomes of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in adults with overweight or obesity and antipsychotic‐treated schizophrenia‐spectrum disorders. Methods PubMed/MEDLINE, Embase, PsycINFO, CENTRAL, Virtual Health Library (VHL) (Biblioteca Virtual em Saúde, BVS),
Débora Regina de Aguiar   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy